Department of Hepatobiliary Surgery, Cancer Hospital of Tianjin Medical University, Huanhu Western Road, Hexi District, Tianjin 300060, China.
World J Gastroenterol. 2010 Feb 14;16(6):764-9. doi: 10.3748/wjg.v16.i6.764.
To clarify the therapeutic strategies and prognosis factors of primary clear cell carcinoma of the liver (PCCCL).
The clinical pathological data of 64 patients with PCCCL treated with hepatectomy in our hospital from January 2000 to January 2006 were analyzed retrospectively. The patients were divided into two groups to make treatment analysis: curative resection only (n = 40); and curative resection and postoperative chemotherapy with calcium folinate and tegafur (n = 24). Meanwhile, the PCCCL patients were subdivided into two subgroups on the basis of the proportion of clear cells in the tumor for pathological analysis. There were 36 cases in subgroup A for which the proportion of clear cells was more than 70%, and 28 cases in subgroup B for which the proportion was less or equal to 70%, comparing analysis of median survival time of the counterpart groups. Univariate and multivariate analyses were performed to examine factors that affected clinical prognosis, recurrence and metastasis.
Median survival period of the curative surgery group was 38 mo, while the counterpart was 41 mo. Median survival period for group A was 41 mo, while group B was 19 mo. The Kaplan-Meier method showed that capsule formation, preoperative liver function, hepatitis C virus infection, large vascular invasion and multiple tumor occurrences were related to disease-free survival. Cox regression analysis showed that the clear cell ratio, capsule formation, preoperative liver function and large vascular invasion were independent risk factors for overall survival.
Postoperative chemotherapy has no obvious effect on survival of patients with PCCCL. Clear cell ratio, capsule formation, preoperative liver function, and vascular invasion were independent risk factors for prognosis.
阐明原发性透明细胞肝癌(PCCCL)的治疗策略和预后因素。
回顾性分析我院 2000 年 1 月至 2006 年 1 月间行肝切除术治疗的 64 例 PCCCL 患者的临床病理资料。根据治疗方法的不同将患者分为两组进行治疗分析:单纯根治性切除术(n=40);根治性切除术联合术后亚叶酸钙和替加氟化疗(n=24)。同时,根据肿瘤中透明细胞的比例将 PCCCL 患者分为两组进行病理分析。其中透明细胞比例大于 70%的患者 36 例归入 A 亚组,比例小于或等于 70%的患者 28 例归入 B 亚组,比较两组患者的中位生存时间。采用单因素和多因素分析方法来检测影响临床预后、复发和转移的因素。
根治性手术组的中位生存时间为 38 个月,对照组为 41 个月。A 组的中位生存时间为 41 个月,B 组为 19 个月。Kaplan-Meier 法显示包膜形成、术前肝功能、丙型肝炎病毒感染、大血管侵犯和多发肿瘤与无病生存率有关。Cox 回归分析显示透明细胞比例、包膜形成、术前肝功能和大血管侵犯是总生存率的独立危险因素。
术后化疗对 PCCCL 患者的生存无明显影响。透明细胞比例、包膜形成、术前肝功能和血管侵犯是独立的预后危险因素。